PSA doubling time predicts survival in PCa patients

Article

In a study confirming other recent research, researchers at M.D. Anderson Cancer Center, Houston have found that the speed of PSA rise following treatment with hormone and radiation therapies can help predict survival in prostate cancer patients.

In a study confirming other recent research, researchers at M.D. Anderson Cancer Center, Houston, have found that the speed of PSA rise following treatment with hormone and radiation therapies can help predict survival in prostate cancer patients. The study examined 621 men treated for the disease between 1989 and 2003. Patients whose PSA level doubled within 8 months after treatment failure were more likely to have cancer return or metastasize.

The estimated 5-year rate of clinical failure among patients with a PSA doubling time of more than 8 months was only 9.4%, while 60.4% of patients whose PSA doubling time was less than or equal to 8 months could expect some type of clinical failure, according to lead author Andrew K. Lee, MD.

Study results appear in the International Journal of Radiation Oncology*Biology*Physics (2005; 63:456-62).

Related Videos
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
John Michael DiBianco, MD, answers a question during a Zoom video interview
Shaya Taghechian, MD, answers a question during a video interview
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
A panel of 4 experts on prostate cancer
Joseph Song, MD, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.